AngioDynamics upgraded at Oppenheimer on pipeline progress [Seeking Alpha]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Seeking Alpha
Perform, citing the FDA's recent decision to expand the use of its AlphaVac F18 medical device. After the FDA approved the clot-clearing device for pulmonary embolism in addition to its current indication for venous thromboembolism, AngioDynamics ( ANGO ) shares closed ~5% higher on Thursday. As reasons for the upgrade, Oppenheimer's Steven Lichtman cited earlier-than-expected FDA clearance, the company's recent patent settlement with Becton, Dickinson ( BDX ), and its more robust financial position after recent non-core divestments. "While competition in ANGO's core market remains stiff, new pipeline products are close to contributing, the company has strengthened its balance sheet, and the shares trade at less than 1x FY25E EV/sales," Lichtman wrote. Oppenheimer issued a $12 per share target on the stock. Recommended For You More Trending News Recommended For You More Trending News About ANGO Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- Insider Spends US$67k Buying More Shares In AngioDynamics [Yahoo! Finance]Yahoo! Finance
- A Leaner AngioDynamics Is A High-Risk Execution-Driven Story [Seeking Alpha]Seeking Alpha
- AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment [Yahoo! Finance]Yahoo! Finance
- AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates [Yahoo! Finance]Yahoo! Finance
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- 4/4/24 - Form 8-K
- ANGO's page on the SEC website